Cardiac Toxicity of Alectinib in Patients With ALK+ Lung Cancer: Outcomes of Cardio-Oncology Follow-Up.

Pruis, Melinda A; Veerman, G D Marijn; Hassing, H Carlijne; Lanser, Daan A C; Paats, Marthe S; van Schaik, Ron H N; Mathijssen, Ron H J; Manintveld, Olivier; Dingemans, Anne-Marie C

Cardiac Toxicity of Alectinib in Patients With ALK+ Lung Cancer: Outcomes of Cardio-Oncology Follow-Up.

Pruis, Melinda A; Veerman, G D Marijn; Hassing, H Carlijne; Lanser, Daan A C; Paats, Marthe S; van Schaik, Ron H N; Mathijssen, Ron H J; Manintveld, Olivier; Dingemans, Anne-Marie C.

Afiliación

Pruis MA; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, the Netherlands.
Veerman GDM; Department of Pulmonary Medicine, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, the Netherlands.
Hassing HC; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, the Netherlands.
Lanser DAC; Department of Cardiology, Erasmus MC, University Medical Centre, Rotterdam, the Netherlands.
Paats MS; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, the Netherlands.
van Schaik RHN; Department of Pulmonary Medicine, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, the Netherlands.
Mathijssen RHJ; Department of Clinical Chemistry, Erasmus MC, University Medical Centre, Rotterdam, the Netherlands.
Manintveld O; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, the Netherlands.
Dingemans AC; Department of Cardiology, Erasmus MC, University Medical Centre, Rotterdam, the Netherlands.

JACC CardioOncol ; 5(1): 102-113, 2023 Feb.

Article en En | MEDLINE | ID: mdl-36875894

Palabras clave

AE, adverse event; ALK, anaplastic lymphoma kinase; CV, cardiovascular; ECG, electrocardiogram; IVC, inferior vena cava; LVEF, left ventricular ejection fraction; MET, mesenchymal epithelial transition; NSCLC, non-small cell lung cancer; OV, outpatient visit; PK, pharmacokinetic; TKI, tyrosine kinase inhibitor; alectinib; anaplastic lymphoma kinase; bradycardia; cardio-oncology; non-small cell lung cancer

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: JACC CardioOncol Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google